Holen Sie sich die Stockscreener-App
17.50
0.29%
0.05
Vorhandelsmarkt:
17.76
0.26
+1.49%
Schlusskurs vom Vortag:
$17.45
Offen:
$17.38
24-Stunden-Volumen:
297.05K
Relative Volume:
0.61
Marktkapitalisierung:
$6.16B
Einnahmen:
$4.68B
Nettoeinkommen (Verlust:
$-368.00M
KGV:
-16.67
EPS:
-1.05
Netto-Cashflow:
$-58.00M
1W Leistung:
+0.52%
1M Leistung:
-1.35%
6M Leistung:
+7.16%
1J Leistung:
+25.18%
1-Tages-Spanne:
$17.28
$17.72
1-Wochen-Bereich:
$16.98
$18.14
52-Wochen-Spanne:
$13.16
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.50 | 6.16B | 4.68B | -368.00M | -58.00M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
579.65 | 206.74B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
242.42 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
91.57 | 45.29B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
240.46 | 35.33B | 4.93B | 1.25B | 1.38B | 8.47 |
|
WST
West Pharmaceutical Services Inc
|
331.04 | 24.01B | 2.88B | 499.60M | 321.60M | 6.74 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) Target Price at $20.25 - MarketBeat
Stifel Nicolaus Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 - GlobeNewswire Inc.
Bausch Lomb Corporation (BLCO-T) QuotePress Release - The Globe and Mail
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19 - Business Wire
This Bausch + Lomb Insider Increased Their Holding In The Last Year - Yahoo Finance
Ellsworth Advisors LLC Invests $665,000 in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Wells Fargo & Company Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $24.00 - Defense World
Bausch + Lomb bolsters pipeline with acquisition of Whitecap Biosciences - ROI-NJ.com
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences - BioSpace
Bausch + Lomb Launches enVista Aspire IOLs in Europe - TipRanks
Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union - Business Wire
Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20? - Yahoo Finance
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine - Yahoo Finance
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy - Yahoo Finance
Implantable Drug Delivery Devices Business Research Report 2023-2024 & 2030 - GlobeNewswire Inc.
S&P 500 Futures Rise in Premarket Trading; Aurora Innovation, Bausch + Lomb Lead - Barron's
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge - Business Wire
Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Shares Acquired by State Street Corp - Defense World
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Warburg Pincus to buy Bausch & Lomb for $3.67 bln - Reuters
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - Yahoo Finance
Bausch + Lomb down after report that Blackstone could back away from takeover bid - MSN
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Y Intercept Hong Kong Ltd Makes New Investment in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Short Interest in Bausch + Lomb Co. (NYSE:BLCO) Rises By 11.7% - MarketBeat
Janus Henderson Group PLC Purchases New Shares in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch And Lomb Says Potential Sale In The Works - Law360
Bausch + Lomb exploring several options including a potential sale - Coast Reporter
Contact lens maker Bausch + Lomb says it is exploring sale - Reuters
Bausch + Lomb confirms it is exploring a potential sale - Financial Post
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):